Literature DB >> 28835406

Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

Heinz Wiendl1, Dennis Bourdette2, Olga Ciccarelli2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28835406     DOI： 10.1212/WNL.0000000000004381

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

Review 1.  [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Authors:  Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp
Journal:  Nervenarzt       Date:  2021-07-23       Impact factor: 1.214

2.  Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.

Authors:  Micha Simon; Rojda Ipek; György A Homola; Damiano M Rovituso; Andrea Schampel; Christoph Kleinschnitz; Stefanie Kuerten
Journal:  J Neuroinflammation       Date:  2018-08-11       Impact factor: 8.322

3.  Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.

Authors:  Heinz Wiendl; Matthew Carraro; Giancarlo Comi; Guillermo Izquierdo; Ho Jin Kim; Basil Sharrack; Carlo Tornatore; Nadia Daizadeh; Luke Chung; Alan K Jacobs; Richard J Hogan; Linda V Wychowski; Bart Van Wijmeersch
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-10-29

4.  Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.

Authors:  Bart Van Wijmeersch; Barry A Singer; Aaron Boster; Simon Broadley; Óscar Fernández; Mark S Freedman; Guillermo Izquierdo; Jan Lycke; Carlo Pozzilli; Basil Sharrack; Brian Steingo; Heinz Wiendl; Sibyl Wray; Tjalf Ziemssen; Luke Chung; David H Margolin; Karthinathan Thangavelu; Patrick Vermersch
Journal:  Mult Scler       Date:  2019-11-01       Impact factor: 6.312
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.